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Background. Our aim was to study the incidence and pattern of dyslipidemia among human immunodeﬁ-
ciency virus (HIV)–infected patients with tuberculosis (TB) who received once-daily antiretroviral therapy (ART).
Methods. Antiretroviral-naive HIV-infected patients with TB were recruited to a trial of once-daily nonnucleoside
reverse-transcriptase inhibitor (NNRTI)–based ART and treated with rifampicin-based thrice-weekly antituberculosis
treatment (ATT); participants were randomized to receive didanosine (250/400 mg) and lamivudine (300 mg) with
either efavirenz (600 mg) or nevirapine (400 mg) once-daily after an intensive phase of ATT. Fasting triglyceride (TG)
level, total cholesterol (TC) level, low-density cholesterol (LDL-c) level and high-density cholesterol (HDL-c) level were
measured at baseline and at 6 and 12 months. Lipid levels at 6 and 12 months were compared with baseline values with
useofrepeated measures analyses. McNemar test was used to comparetheproportionofpatientswithlipidabnormality
at baseline versus at 12 months, and v
2 test was used to compare between the 2 groups.
Results. Of 168 patients (79% men; mean age, 36 years; mean weight, 42 kg; median CD41 cell count, 93 cells/
mm
3), 104 received efavirenz-based ART, and 64 received nevirapine-based ART. After 6 months, TC levels
increased by 49 mg/dL, LDL-c levels by 30 mg/dL, and HDL-c levels increased by 18 mg/dL (P , .001 for all). At
baseline and at 12 months, TC was .200 mg/dL for 1% and 26% of patients, respectively; LDL-c level was .130mg/
dL for 3% and 23%, respectively; HDL-c level was ,40 mg/dL for 91% and 23%, respectively; and blood glucose
level was .110 mg/dL for 14% and 13%, respectively. TC level .200 mg/dL was more common among patients
who received efavirenz than among those who received nevirapine (32% vs 16%; P 5 .04).
Conclusions. HIV-infected patients with TB who initiate NNRTI-based ART undergo complex changes in lipid
proﬁle, highlighting the importance of screening and treating other cardiovascular disease risk factors in this population.
Dyslipidemia is a well-recognized complication of
human immunodeﬁciency virus (HIV) infection and
of highly active antiretroviral therapy (HAART), and
it has been linked to an increased risk for cardiovas-
cular morbidity in HIV-1–infected patients [1]. Pre-
vious studies have shown that some antiretroviral
drugs, such as stavudine and protease inhibitors (PI),
increase blood levels of total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-c), and trigly-
cerides (TG) and have variable effects on levels of
high-density lipoprotein cholesterol (HDL-c) [2,3].
By contrast, antiretroviral therapy (ART) regimens
containing nonnucleoside reverse-transcriptase
inhibitors (NNRTIs) have been less well studied, al-
though receipt of nevirapine is associated with less
atherogenic lipid proﬁles [4].
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netically different populations from countries such as India are
scarce. With the dramatic scale-up of access to ART in many
countries with differing baseline risk factors for cardiovascular
disease (CVD), it is important to determine the prevalence of
ART-associatedcomplications,suchasdyslipidemia,indifferent
patient populations. Patients initiating ART in these settings
may experience different rates and types of lipid abnormalities
than patients in resource-sufﬁcient countries because of differ-
ences in genetic background, dietary intake, and lifestyle factors.
In addition, patients in resource-limited settings are more likely
to have advanced HIV disease and poor nutritional status and to
begin treatment with non PI-based regimens.
A small study from Pune, India, found that treatment with
stavudine, lamivudine, and nevirapine was associated with
substantial increases in TC and TG levels in HIV-infected pa-
tients treated for 18–20 months [5]. However, with respect to
the widely used ﬁrst-line ART regimens in India, which are
nevirapine-orefavirenz-based,therearenocomparativedataon
the differing effects of these regimens on plasma lipids in this
population. We studied lipid proﬁles before initiation and after
6 and 12 months of a once-daily NNRTI-based antiretroviral
regimen, given along with antituberculosis treatment (ATT), in
adults with HIV and tuberculosis (TB) co-infection who par-
ticipated in a once-daily ART clinical trial in Tamilnadu, India.
METHODS
This dyslipidemia study was nested within a prospective ran-
domized controlled clinical trial called ‘‘Efﬁcacy and Safety of
Once Daily Nevirapine or Efavirenz Based Antiretroviral Ther-
apy when Co-administered with Rifampicin Based Antituber-
cular Therapy (ClinicalTrials.gov Number: NCT00332306).’’
HIV-1–infected adults with active TB and with CD41 cell
counts ,250 cells/mm
3 seen at the Tuberculosis Research
Centre,India,fromMay2006 throughJune2008 wereeligibleto
participate. Patients with prior ART or ATT, HIV-2 infection,
substance abuse, major complications of HIV disease, psychi-
atric illnesses, or serum transaminase levels .2.5 times the
upper limit of normal were excluded.
This planned sub-study of the ‘‘Once-daily ART’’ trial col-
lected additional clinical and laboratory data as part of the trial
to monitor the safety and efﬁcacy of administering different
ART regimens in combination with rifampicin-based ATT.
Therefore, it was possible to study the development and evo-
lution of dyslipidemia prospectively in this study.
All patients enrolled in the ‘‘Once-daily ART’’ study initiated
a standard anti-TB regimen with 4 drugs (isoniazid 600 mg;
rifampicin 450 or 600 mg, determined on the basis of body
weight <60 or .60 kg, respectively; ethambutol 1200 mg; and
pyrazinamide 1500 mg) for the ﬁrst 2 months and 2 drugs
(isoniazid and rifampicin) for the subsequent 4 months. All
drugs were administered thrice-weekly (2EHRZ3/4RH3)u n d e r
direct observation in accordance with national guidelines. After
the ﬁrst 2 months of ATT, participants were randomized to
a once-daily ART regimen with either nevirapine (400 mg per
day, after a lead-in period of 200-mg doses administered once
daily) or efavirenz (600 mg per day), along with didanosine (250
or 400 mg per day for body weight ,60 or >60 kg, respectively)
and lamivudine (300 mg per day).
The time of ATT initiation was deﬁned as Month -2 (ie, 2
months before the initiation of ART), and time of ART initia-
tion was deﬁned as month 0 or baseline. Subsequent months are
chronological with reference to month 0. ART was administered
under direct supervision 3 days per week and supplied to the
patient for self administration for the remaining days. Although
ATT was stopped at 6 months, which was month 4 of the ART
study, ART was continued (Figure 1), and end points were de-
termined.
Study Population and Data Collection
During the 12-month follow-up period, participants were ex-
amined clinically every month, and height and weight were
measured. Blood samples were collected after a 12-h overnight
fast for glucose and lipid proﬁle (TC, TG, LDL-c and HDL-c) at
baseline, 6 and 12 months after ART in accordance with the
randomized trial protocol. Glucose and lipid proﬁles, including
TG, TC, HDL-c, and LDL-c levels, were measured using an
automated analyzer (Olympus AU400, Japan), CD41 cell
counts were measured by FACS count, and viral load was
measured by Roche COBAS Amplicor (kit version 1.5) every
6 months.
Dyslipidemia was deﬁned according to the US National
Cholesterol Education Program III guidelines [6]. These include
TC level .200 mg/dL, LDL-c level .130 mg/dL, triglyceride
level .150 mg/dL, and HDL-c level ,40 mg/dL. Fasting hy-
perglycemia was deﬁnedas blood glucose level .110 mg/dL. For
the purposes of our study, an elevation of any one of the lipid
parameters to a level above these limits was considered as an
abnormal lipid proﬁle.
Statistical Analysis
The distribution of each variable was checked cross-sectionally
at baseline and at 6 and 12 months. All unusual values were
veriﬁed. Mean values and standard deviations were tabulated
for normally distributed variables; median values and 25
th and
75
th percentiles were tabulated for skewed variables. We
compared baseline lipid levels and various baseline de-
mographic and clinical characteristics between treatment
groups using the Student’s t test or the Wilcoxon rank-sum
test, as appropriate. Lipid levels at 6 and 12 months were
compared with baseline levels using repeated measures analy-
ses, with skewed variables transformed to attain normality. We
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groups using repeated measures analyses. We compared the
proportion of patients with lipid abnormality at baseline versus
at 12 months using the McNemar test for correlated pro-
portions and the v
2 test to compare between the 2 treatment
groups. All tests used alpha5.05 as the cutoff point for statis-
tical signiﬁcance. Analyses were performed using SAS software,
version 9.1 (SAS Institute).
The study was approved by the ethics committee of the Tu-
berculosis Research Centre, and written informed consent was
obtained from all patients prior to enrollment in the primary
randomized controlled trial.
RESULTS
Of the 179 patients enrolled into the once-daily ART study, 168
patients (132 men and 36 women) were eligible for the current
analysis (11 were not randomized). Follow-up data were available
for 140patients at 6 and 12months (15 patients died, 11were lost
to follow-up, and 2 missed study visits). Data from patients who
died or were lost to follow-up were not included in this analysis.
Patient Characteristics
At baseline, the 168 HIV-infected patients with TB (male sex,
79%) had a mean age of 36 years, mean body weight of 42 kg,
Figure 1. Schematic of once-daily ART study design. 3TC, lamivudine; ATT, antituberculosis treatment; ART, antiretroviral therapy; CD4, CD41 cell
count; ddI, didanosine; EFV, efavirenz; exam, examination; HIV, human immunodeficiency virus; LFT, liver function test; NVP, nevirapine; RMP, rifampin; TB,
tuberculosis VL, viral load.
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3, and a mean HIV
load of 362,154 copies/mL. A total of 104 patients were ran-
domized to the efavirenz arm, and 64 were randomized to the
nevirapine arm (the Data Safety Monitoring Board stopped
enrollment of patients into the nevirapine arm after the ﬁrst
interim analysis but allowed enrollment to continue in the efa-
virenz arm). At baseline, patients did not differ signiﬁcantly
between the 2 treatment arms with respect to body weight,
CD41 cell counts, viral load, lipid proﬁle, or liver enzyme levels
(Table 1). Forty-four percent of the patients consumed alcohol
(often or habitually). Drug intake was directly observed 3 days
a week, overall adherence was .90%, and the majority of sub-
jects had undetectable HIV loads after 12 months of ART.
Baseline Lipids
The baseline lipid levels were comparable by treatment group,
sex,andbodyweight.TGlevelsweresigniﬁcantlyhigherinthose
patients with higher viral loads (141 vs 122 mg/dL; P , .03).
HDL-c levels were lower in persons ,35 years of age (25 vs 28
mg/dL; P 5 .03) and those with CD41 cell counts ,90 cells/
mm
3 (24 vs 29 mg/dL; P 5 .01). These cutoff values were based
on the median levels of the baseline demographic characteristics
(data not shown). At baseline, TG level was .150 mg/dL in 44
patients (31%), TC level was .200 mg/dL in 2 patients, HDL-c
was ,40 mg/dL in 124 patients (91%), LDL-c was .130 mg/dL
in 4 patients (3%), and plasma glucose level was .110 mg/dL in
19 patients.
Longitudinal Lipid Values
After 6 months of ART, signiﬁcant increases were observed in TC
level(125vs174mg/dL;P , .001), LDL-c level (83 vs 112 mg/dL;
P , .001), and HDL-c level (26 vs 44 mg/dL; P , .001) (Table 2).
At 12 months of ART, patient mean weight was 50.5 kg, and
median CD41 cell count had increased from 90 to 363 cells/mm
3.
A ss h o w ni nT a b l e2 ,t h eT C ,L D L - c ,f a s t i n gg l u c o s e ,a n dH D L - c
levels were signiﬁcantly higher at 12 months than at baseline. The
TG levels were comparable (P 5 .72). After 12 months of treat-
ment, TC level increased by a mean of 54 mg/dL, and LDL-c level
increased by 30 mg/dL, whereas HDL-c level increased by a mean
of 23.6 mg/dL (median increase, 21 mg/dL) (Table 2).
At 12 months, the proportion of patients with TC levels .200
mg/dL had increased signiﬁcantly, from 1% to 26% (P , .001).
However,theproportion ofpatients with HDL-c levels,40mg/
dL decreased signiﬁcantly, from 91% to 23% (P , .001). The
proportion of patients with TG levels .150 mg/dL did not
change signiﬁcantly (31% vs 32%; P 5 .89) nor did the pro-
portion of patients withfasting glucose levels.110mg/dL (14%
vs 13%), as shown in Table 3.
Changes in Lipid Levels by Type of ART Regimen
We found no statistically signiﬁcant differences between the
nevirapine and efavirenz groups in mean lipid and glucose level
changes. However, the proportion of patients at 12 months with
total cholesterol .200 mg/dL was signiﬁcantly higher in the
efavirenzarmthaninthenevirapinearm(32%vs16%;P5.04).
The proportion of patients with other abnormal lipid parame-
ters was not statistically different between the groups (Table 4).
No signiﬁcant changes were observed in plasma glucose levels in
either group. At 12 months, of the 36 patients who had an
elevated total cholesterol level (.200 mg/dL), only 3 patients
had a detectable viral load (viral load .400 copies/mL), whereas
the rest had viral loads ,400 copies/mL.
DISCUSSION
In this cohort of patients in South India with TB and advanced
HIV disease, who were treated with both anti-TB and anti-
retroviral drugs, we found that, at baseline, total cholesterol,
Table 1. Demographic and Clinical Characteristics of Patients at Baseline
Variable
Patients receiving
ddI/3TC/EFV (n 5 104)
Patients receiving
ddI/3TC/NVP (n 5 64) P
Age, years 35 (6.9) 37 (7.7) .06
Weight, kg 41.9 (7.9) 42.0 (7.7) .89
Male sex, no. (%) of patients 81 (78) 51 (80) .78
Alcohol habituated, no. (%) of patients 43 (41) 31 (48) .14
CD41 cell count, median cells/mm
3 (IQR) 90 (53–130) 75 (34–130) .14
Viral load, median copies/mL (IQR) 259000 (81200–531000) 203000 (87900–370000) .79
Triglycerides level, median mg/dL (IQR) 123 (96–164) 113 (92–173) .74
HDL-cholesterol level, median mg/dL (IQR) 26 (20–32) 24 (20–32) .66
Total cholesterol level, mg/dL 124 (34) 126 (32.6) .65
LDL-c level, mg/dL 82 (26) 79 (25.9) .49
Fasting glucose level, mg/dL 97 (26) 91 (13) .11
NOTE. Data are mean values (6 standard deviation) unless otherwise indicated. For comparison between groups, the Student’s t test was used for mean
values and the Wilcoxon rank-sum test was used for median values. 3TC, lamivudine; ddI, didanosine; EFV, efavirenz; HDL-c, high-density lipoprotein cholesterol;
IQR, interquartile range; LDL-c, low-density lipoprotein cholesterol; NPV, nevirapine.
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wereinthenormalrange.Fastingglucoselevelwasinthenormal
range at baseline and remained so throughout the study. After
12 months of successful NNRTI-based ART, HDL levels, as well
as total and LDL cholesterol levels, increased signiﬁcantly. The
major changes in lipid proﬁles occurred during the ﬁrst 6
months of ART and were maintained without signiﬁcant change
thereafter. At 1 year, there was no difference in the overall lipid
proﬁles between patients who received nevirapine and those
who received efavirenz-based regimens. Although HDL levels
increased in the majority of patients who received treatment,
a signiﬁcant proportion (23%) continued to have levels below
the lower limit of normal. There was an increase in the number
of patients with abnormal TC levels (26%) at the end of the
study, regardless of the ART regimen.
Studies in resource sufﬁcient countries have documented that
patients with advanced HIV infection have decreased levels of
TC, LDL-c and HDL-c, with the extent of lipid abnormalities
correlating with disease severity. TC and LDL-c levels routinely
show an increase with the use of effective ART [7–9]. Recent
ﬁndings suggest that the use of NNRTI-based therapy results in
an elevation in HDL-cholesterol levels and therefore may be less
atherogenic than protease inhibitor–based treatments [10].
Nevirapine-containing regimens have been associated with
more-favorable changes in lipid proﬁles (lesser increase in TC,
TG, LDL-c levels and greater increase in HDL-c levels) than
efavirenz-containing regimens [11, 12]. Although we did not
ﬁnd major differences in lipid proﬁles between the 2 NNRTI
treatment regimens, a greater proportion of patients who re-
ceived efavirenz developed TC levels .200 mg/dL after 12
months of treatment. Because of multiple testing, this ﬁnding
should be interpreted with caution.
The patients in our study had both advanced HIV and TB,
which will continue to be a frequent occurrence in individuals
startingARTinresource-limitedareas.Thebaselinelipidproﬁles
may somewhat reﬂect the severity of nutritional compromise
seen with these co-morbidities. The changes that we observed in
lipid proﬁles in this study (namely, increased TC, HDL-c, and
LDL-c levels) may therefore, at least in part, represent the return
to normal lipid values when both TB and HIV infection are
treated, inﬂammation decreases, nutritional status and immune
function improve, and HIV viremia is controlled. Patients who
showed an increase in lipid levels in our study were all virolog-
ically suppressed after 12 months of ART and all gained weight.
Table 2. Pattern of Change in Serum Lipid Levels for the Overall Group receiving Once-Daily Nonnucleoside Reverse-Transcriptase
Inhibitor–Based Antiretroviral Therapy
Lipid parameter
Baseline
(n 5 140)
At 6 months
(n 5 140)
Change at
6 months
P
a (6 months
vs baseline)
At 12 months
(n 5 140)
Change at
12 months
P
a (12 months
vs baseline)
Triglyceride levels, median
mg/dL (IQR)
119 (94, 164) 125 (96, 172) 6 (-35, 51) 0.50 121 (88, 165) 1 (-44, 47) 0.72
HDL-c level,median mg/dL
(IQR)
26 (20, 33) 44 (38, 53) 18 (13, 28) ,.0001 47(40, 55) 21(13, 33) , .0001
Total cholesterol level, mean
mg/dL (6SD)
125633.5 174640.1 49643.2 ,.0001 179637.6 54642.6 , .0001
LDL-c level, mean mg/dL (6SD) 82.7626 112629.6 29.6632 ,.0001 113628.2 30.5634 , .0001
Fasting glucose level, mean mg/dL
(6SD)
94624 98620 4630.9 0.20 99617.2 5629.4 0.19
NOTE. Log triglyceride levels and square root HDL were used in the repeated measures analyses to attain normality for the skewed variables. HDL-c, high-
density lipoprotein cholesterol; IQR, interquartile range; LDL-c, low-density lipoprotein cholesterol; SD, standard deviation.
a P values were calculated with repeated measures analyses in Proc Mixed.
Table 3. Comparing Proportion of Patients with Abnormal Lipid and Glucose Levels at Baseline and after 12 Months of ART
No. (%) of patients with abnormal lipid levels
After 12 monthsof ART (n 5 140)
Lipid parameters
Atbaseline
(n 5 140) Total
Newly
developed
Persisted
from baseline P
a
Total cholesterol level .200 mg/dL 2 (1.4) 37 (26) 36 (26) 1 , .001
Triglyceride level .150 mg/dL 44 (31) 45 (32) 28 (20) 17 (12) .89
HDL cholesterol level ,40 mg/dL 124 (91) 31 (23) 0 31 (23) , .001
LDL cholesterol level .130 mg/dL 4 (3) 32 (23) 31 (23) 1 , .001
Fasting blood glucose level .110 mg/dL 19 (14) 17 (13) 15 (11) 2 .13
NOTE. ART, antiretroviral therapy.
a Comparing the proportion of patients with abnormal lipid levels at baseline and at 12 months with use of McNemar test.
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with a signiﬁcantly increased proportion of patients who de-
veloped abnormally high levels. But the changes in HDL-c level
were advantageous, with a signiﬁcant decrease in the proportion
of patients who had abnormally low HDL levels. A sizeable
proportion of patients in our study (23%), however, continued
to demonstrate a low level of HDL cholesterol.
A study from Pune, India, looked at the lipid proﬁle of
patients receiving ART (stavudine, lamivudine, and nevir-
apine) for a mean of 20 months [5]. Their study population
was roughly comparable by age and immunologic status to our
study population but did not include patients with active TB
[5]. In that study, 41% of patients, compared with 26% of the
patients in our study, developed TC levels .200 mg/dL,
whereas 45% of their patients, in contrast to 32% of our pa-
tients, developed TG levels .150 mg/dL. This increase in the
proportion of patients who showed abnormallevels in the Pune
study may be attributable to differences in TB co-infection,
socioeconomic status, longer duration of treatment, and diet,
all of which can affect lipid changes in patients receiving ART.
A study from Uganda involving patients who received stavu-
dine, lamivudine, and either nevirapine or efavirenz and were
followed-up for 24 months, recorded a 10% increase in the
number of patients with TC levels .200 mg/dL, a 20% increase
in patients with TGL levels .200 mg/dL, and 6% increase in
the number of patients with LDL-c level .150 mg/dL at the
end of 24 months [13]. The increases in HDL-c and TC level in
our study are similar to those in the 2NN study (which was
an open-label, randomized, comparative trial of ﬁrst-line ART
in treatment-naive patients, with regimens based on stavudine
plus lamivudine plus either efavirenz or nevirapine dosed either
at 400 mg once or 200 mg twice daily or both NNRTIs ad-
ministered simultaneously), where an increase in HDL-c level
of 49% was seen in the nevirapine arm [8]. There are no studies
from India that compare the lipid proﬁle between these 2
different NNRTIs.
W ed i dn o tﬁ n dm a r k e dd i f f e r e n c e sb ys e xi np r e - t r e a t m e n to r
post-treatmentlipidlevels,whichhavebeendocumentedinstudies
ofHIV-infectedpatientselsewhere[8]. However, all of the patients
in our study had low pretreatment lipid levels, likely resulting
from advanced HIV infection or AIDS, infection with TB, serious
undernutrition, or poor dietary intake. These factors may have
diminished potential differences,i fa n y ,i nl i p i dp r o ﬁ l e sb ys e x .
Our ﬁndings should be interpreted within the context of the
study and its limitations. We did not collect individual-level
dietary history and cannot comment on the role of dietary in-
take. We do not have data on regional body composition or
blood pressure, so we were unable to assess the risk of metabolic
syndrome or coronary heart disease or develop predictors for
the same in this population. Furthermore, our follow-up end
point at 12 months may not have been enough to assess long-
term changes in lipids.
The Indian population in general has a high risk of cardio-
vascular disease (because of genetic and other factors), and there
is concern that HIV infection and treatment with ART may
increase that risk [14]. Our observations that 25% of patients
who receive an NNRTI-based regimen have an abnormal lipid
proﬁle at 1 year should alert physicians to this outcome and
encourage testing. Although the current World Health Organi-
zation guidelines do not recommend routine monitoring of
lipid levels for patients receiving ﬁrst-line antiretroviral treat-
ment [15], patients would beneﬁt from an assessment of lipid
proﬁles and other cardiovascular risk factors followed by
counseling on risk-reduction strategies. As patients continue to
enjoy longer lives as a result of effective treatment, it is impor-
tant to consider and minimize long-term adverse effects of the
disease and its treatment.
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